Abstract Library

#2933 The Clinicopathological Characteristics of Gastrinoma: A Single-Center Retrospective Study

Introduction: Gastrinoma is a rare functional neuroendocrine tumor leading to gastrin hypersecretion and hyperchlorhydria.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Liu M, Chen L, Guo Y, Chen M,

Keywords: gastrinoma, functional neuroendocrine tumor,

#1503 Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study

Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Buzzoni R

Authors: Buzzoni R, Carnaghi C, Pommier R, Fazio N, Singh S,

Keywords: everolimus, SSA, nonfunctional NET,

#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis

Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Singh S

Authors: Singh S, Carnaghi C, Buzzoni R, Raderer M, Lahner H,

Keywords: Everolimus, progression-free survival, gastrointestinal NET,

#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study

Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Fazio N

Authors: Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E,

Keywords: PFS, Everolimus, Lung carcinoid,

#1050 Recurrent Disease After Curative Pancreatic Resection for Patients with Non-Functional Neuroendocrine Tumor; Identify the High Risk Patient

Introduction: Since the overall favourable survival, detection of recurrent disease is one of the main goals during follow up in patients with resected pancreatic neuroendocrine tumors (pNET).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Jilesen A

Authors: Jilesen A, Van Eijck C, Van Kemenade F, Van Eeden S, Verheij J,

Keywords: NF,